Medical Marijuana Alert: Food and Drug Administration (FDA) Approves First Drug Derived from Marijuana

The United States Food and Drug Administration (FDA) has approved the first drug derived from marijuana.  The drug, which was created by GW Pharmaceuticals from a proprietary strain of cannabis, is made from Cannabidiol (often referred to as CBD), which is a cannabinoid that is not psychoactive (i.e., does not provide a high).  The drug, which is called Epidiolex, reduces seizures in epileptic patients.

Before Epidiolex can be marketed, the United States Drug Enforcement Agency will have to reclassify CBD, which is currently a Schedule I drug, as a Schedule II or Schedule III drug.

If you have any questions regarding the legal developments regarding Epidiolex or Louisiana's medical marijuana program, please do not hesitate to contact our firm.

          Author:   Keith J. Fernandez, W. Scott Keaty, and Joshua G. McDiarmid
          Practice Area:  Medical Marijuana Law
          Date:  June 25, 2018

Disclaimer: The information provided herein (1) is for general information only; (2) does not create an attorney-client relationship between the author or the author’s firm and the reader; (3) does not constitute the provision of legal advice, tax advice, or professional consulting of any kind; and (4) does not substitute for consultation with professional legal, tax or other competent advisors. Before making any decision or taking any action in connection with the matters discussed herein, you should consult with a professional legal, tax and/or other advisor who should be provided with all pertinent facts relevant to your particular situation. The information provided herein is provided “as is,” with no assurance or guarantee of completeness, accuracy, or timeliness of the information.